Suberohydroxamic acid phenyl ester: Phase II started

TetraLogic began an open-label Phase II trial to evaluate once-daily 1%, twice-daily 0.5% and twice-daily 1% SHAPE for 26 weeks in about 60 patients with stage Ia-IIa CTCL. Responders may continue tre...